Clinical Trial Update: A Safety and Immunogenicity Study in Long-term Treatment of Eculizumab (JSC "GENERIUM", Russian Federation) [Phase 3]

View source ↗

Summary

A Phase 3 safety and immunogenicity trial of long-term eculizumab in patients with Paroxysmal Nocturnal Hemoglobinuria has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Paroxysmal Nocturnal Hemoglobinuria

Drugs mentioned

• Eculizumab (eculizumab)

Snippet

Sponsor: AO GENERIUM | Conditions: Paroxysmal Nocturnal Hemoglobinuria | Phase 3 | Status: COMPLETED